Thank you for downloading the ScaleReady_CaseStudy_G-RexOptimization
In this case study, ScaleReady helped an autologous T cell therapy company rapidly transition to a closed-system process for cell expansion by providing a testing plan to verify that G-Rex500M-CS closed-system bioreactors would meet their immediate cell production requirements and improve cell production efficiency, while adhering to their short timelines for going into clinical trials. In doing so, the company also uncovered small changes to their cell culture protocols that made a big impact on their cell production efficiency.
Latest Insights
Multiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® Bioreactors
Multiply Labs and Wilson Wolf are partnering to automate G-Rex® bioreactors for cheaper, more accessible cell therapy manufacturing. This partnership focuses on automating Wilson Wolf's innovative G-Rex® bioreactors, aiming to revolutionize CGT manufacturing.
Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy
Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.
Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success
Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.
Are you ready to scale?
Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.